within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA06_Vintafolide;

model Vintafolide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.638888888888889e-07,
    adminDuration = 600,
    adminMass = 2.5 / 1000000,
    adminCount = 1,
    Vd = 0.0055,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.003,
    k12 = 3.611111111111112e-07,
    k21 = 3.611111111111112e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Vintafolide</td></tr><tr><td>ATC code:</td><td>L01CA06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.95</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Vintafolide is a folate–drug conjugate developed for targeted cancer therapy, mainly investigated for the treatment of folate receptor-positive solid tumors such as ovarian cancer. It is not currently approved for clinical use after phase III trials failed to meet endpoints.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult cancer patients, as no published human PK data are available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01CA06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Vintafolide;
